296 related articles for article (PubMed ID: 1968358)
1. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
[TBL] [Abstract][Full Text] [Related]
2. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.
Ford JM; Prozialeck WC; Hait WN
Mol Pharmacol; 1989 Jan; 35(1):105-15. PubMed ID: 2563302
[TBL] [Abstract][Full Text] [Related]
3. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi.
Fairchild CR; Moscow JA; O'Brien EE; Cowan KH
Mol Pharmacol; 1990 Jun; 37(6):801-9. PubMed ID: 1972772
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
Lincke CR; van der Bliek AM; Schuurhuis GJ; van der Velde-Koerts T; Smit JJ; Borst P
Cancer Res; 1990 Mar; 50(6):1779-85. PubMed ID: 1968359
[TBL] [Abstract][Full Text] [Related]
7. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
8. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
Baas F; Jongsma AP; Broxterman HJ; Arceci RJ; Housman D; Scheffer GL; Riethorst A; van Groenigen M; Nieuwint AW; Joenje H
Cancer Res; 1990 Sep; 50(17):5392-8. PubMed ID: 1974823
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
10. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance.
Hait WN; Aftab DT
Biochem Pharmacol; 1992 Jan; 43(1):103-7. PubMed ID: 1346493
[TBL] [Abstract][Full Text] [Related]
11. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells.
Thimmaiah KN; Jayashree BS; Germain GS; Houghton PJ; Horton JK
Oncol Res; 1998; 10(1):29-41. PubMed ID: 9613455
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies.
Politi PM; Arnold ST; Felsted RL; Sinha BK
Mol Pharmacol; 1990 Jun; 37(6):790-6. PubMed ID: 1972771
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
14. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.
Yusa K; Tsuruo T
Cancer Res; 1989 Sep; 49(18):5002-6. PubMed ID: 2569930
[TBL] [Abstract][Full Text] [Related]
15. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
Chen G; Teicher BA; Frei E
Anticancer Res; 1996; 16(6B):3499-505. PubMed ID: 9042212
[TBL] [Abstract][Full Text] [Related]
16. The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model.
Ujhazy P; Chen YF; Fredericks W; Ho RL; Mihich E; Baker RM; Ehrke MJ
Cancer Commun; 1990; 2(5):181-8. PubMed ID: 1973358
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
18. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
19. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
de la Torre M; Hao XY; Larsson R; Nygren P; Tsuruo T; Mannervik B; Bergh J
Anticancer Res; 1993; 13(5A):1425-30. PubMed ID: 7902062
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]